Introduction
Tachykinins are a family of small biologically active peptides, originally identified in neurons. The best known mammalian tachykinins are substance P (SP), neurokinin (NK) A and NKB, which act mainly via NK 1 , NK 2 and NK 3 receptors, respectively (Pennefather et al., 2004) . Another tachykinin, hemokinin-1 (HK-1, sequence TGKASQFFGLM-NH 2 ), has now been identified in humans (Kurtz et al., 2002 , Page 2004 ). HK-1 was found in immune cells, rather than in neurons (Zhang et al., 2000) , and it shares a similar amino acid sequence and receptor selectivity with SP (Kurt et al., 2002; Pennefather et al., 2004) . In the intestine, SP and NKA act as neurotransmitters to modulate gut functions such as motility, secretion, blood flow and inflammation (Holzer and Holzer-Petsche, 1997; Castagliuolo et al., 1997) .
SP can also be released from non-neuronal cells (Castagliuolo et al., 1997; Moriarty et al., 2001) , and is considered to act as an autocrine, paracrine or endocrine regulator of secretory, immune and inflammatory responses. HK-1 has been implicated in lymphoid (Zhang et al., 2000; Paige, 2003, Berger et al., 2010) and myeloid (Janelsins et al., 2009 ) cell proliferation and development. This leads to the speculation that the intestinal immune and inflammatory actions of SP could be shared by HK-1. However, the actions of HK-1 in the gastrointestinal system remain largely unknown.
It has been hypothesized that tachykinins might be implicated in inflammatory bowel disease (IBD), by interrupting the crosstalk between the neural and immune systems, promoting acute and chronic intestinal inflammation, and thus contributing to the motor, secretory and immunological disturbances which characterize IBD (Holzer, 1998) . This hypothesis was supported by evidence that overexpression of SP and its preferred NK 1 receptor occurred in the intestinal mucosa of patients with IBD (Mazumdar and Das, 1992; Yamamoto et al., 1996; Goode et al., 2000) . Furthermore, animal studies also suggested a critical role for SP/NK 1 receptor in amplifying intestinal inflammation (Kataeva et al., 1994; JPET#186155 5 Castagliuolo et al., 1997; Di Sebastiano et al., 1999) and even initiating colitis (Lin et al., 2009 ). Recently, our molecular studies demonstrated that TAC4 gene encoding HK-1, together with TAC1 gene encoding SP and TACR1 gene encoding NK 1 receptor, were dramatically unregulated in colonic mucosa of ulcerative colitis patients (Liu et al., 2011) .
Prostaglandin E 2 (PGE 2 ) is one of a number of eicanosoids which are synthesised via cyclooxygenase (COX) and metabolized by 15-hydroxyprostaglandin dehydrogenase (15-PGDH) (Otani et al., 2006) . PGE 2 is the major prostaglandin of the intestine and its role during intestinal inflammation is controversial. PGE 2 and prostaglandin EP4 receptor are required for maintaining the mucosal barrier integrity in experimental models of IBD, presumably through the enhancement of epithelial regeneration (Jiang et al., 2007) , but at higher levels PGE 2 can reduce colonic mucosal barrier integrity (Lejeune et al., 2010) .
Studies on EP4 receptor knock-out mice also suggested a protective role for PGE 2 against inflammation (Kabashima et al., 2002) . On the other hand, PGE 2 may lead to impaired mucosal healing or excessive fibrosis by inhibiting the migration of the colonic lamia propria fibroblasts from Crohn's disease patients (Rieder et al., 2010) . PGE 2 production is increased in IBD (Baumeister et al., 1996) , and it has been suggested as a mediator and/or prognostic marker in IBD (Wiercinska-Drapalo et al., 1999; Sheibanie et al., 2007) . PGE 2 and tachykinins have two-way interactions, in that tachykinins can increase levels of PGE 2 in rat intrapulmonary bronchi (Szarek et al., 1998) ; whereas PGE 2 also stimulates SP release in rat sensory neurons (White, 1996) . Although it is clear that abnormal levels of SP, HK-1 and PGE 2 all occur in IBD, and functional interaction between SP and PGE 2 has been reported in human colonic epithelial cells (Koon et al., 2006) , a mechanistic link between HK-1 and PGE 2 production remains unknown. Given the potential pathological role of HK-1 in IBD, our aim was to explore the inflammatory role for HK-1 in normal human colonic tissue.
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Methods
Patients and specimens
Colon ring segments approximately 5 cm in length were obtained from 20 male and 15 female patients undergoing colectomy for carcinoma (age range 41-72 years). Most specimens were collected from the sigmoid colon (n=27) with some also from ascending colon (n=7), and descending colon (n=1). Segments were taken 10-20 cm away from the site of carcinoma; any specimen appearing macroscopically inflamed or showing abnormal histological features was discarded. Patients who had obstruction or who had undergone radiation or chemotherapy were excluded from our study. This project was approved by the Human Ethics Committees of the University of New South Wales (HREC08310) and South Eastern Sydney and Illawarra Area Health Service (SESIAHS 06/69).
Tissue explant preparation
Surgically resected specimens were obtained within 5 min of removal from patients, immediately placed in ice-cold Krebs-Henseleit solution pre-gassed with carbogen (95% O 2 and 5% CO 2 ) and kept on ice until dissection. Specimens were dissected into smooth muscle and mucosa layers, and kept in Krebs-Henseleit solution at 4 o C overnight. For muscle explants, the mucosa, submucosa, serosa and taenia coli were removed, leaving the circular muscle with a thin layer of longitudinal muscle. For mucosal explants, the submucosa was removed. Adjacent explants (3 x 5 mm, approximate weight 60-120 mg) of colonic mucosa or muscle were placed in 2 ml tissue baths containing Krebs-Henseleit solution maintained at 37 o C, and aerated with carbogen. Explants were not placed under tension, and were allowed to equilibrate for 1 h before being washed and exposed to different treatments before aliquots of bath fluids were collected and snap-frozen for later PGE 2 measurement. At the end of treatments, explants were snap-frozen for RNA or protein (Barnett et al., 1994; Johnson et al., 1995) . Some tissue explants were also pre-incubated with the nerve blocking agent, tetrodotoxin (TTX, 0.1 μ M), for 30 min.
Following the pretreatment with inhibitors, explants were exposed to HK-1 or SP for 4 h.
PGE 2 ELISA
PGE 2 levels released into bath fluid were measured by using PGE 2 ELISA kit according to the manufacturer's instructions. Results (in pg/mg tissue) were expressed as mean ± standard error (SEM).
Quantitative real-time PCR
After incubation, total RNA was extracted from mucosal and muscle explants using the Trizol method followed by a DNase treatment, to remove contaminating DNA. SuperScript The forward primer (fp) and reverse primer (rp) for each gene used in PCR was: COX-1 (official gene name PTGS1), fp 5'-ctc cca gga gta cag cta cga-3' and rp 5'-cca gca atc tgg cga gag a-3'; COX-2 (PTGS2), fp 5'-ggc ttc cat tga cca gag cag-3' and rp 5'-gcc gag gct ttt cta cca ga-3'; 15-PGDH (HPGD), fp 5'-ttg gaa gac tgg aca ttt tgg-3' and rp 5'-cct tca cct cca ttt tgc tt-3'; GAPDH fp 5'-cat gag aag tat gac aac agc ct-3' and rp 5'-agt cct tcc acg ata cca aag t-3'. The PCR cycle consisted of 95°C for 2 min, followed by 40 cycles of 95°C for 15 s, 60°C for 15 s and 68°C for 20 s. In the final step, the melting curve analysis was carried out during gradual temperature elevation from 60°C to 95°C. Experiments were conducted in duplicate, using GAPDH as a housekeeping gene (HKG) and a control smooth muscle sample as a calibrator in each PCR run (Liu et al., 2011) . After amplification, the mRNA level for each gene was expressed as fold change, in which each target gene was normalized to GAPDH, and expressed relative to the calibrator using the formula:
, where (Pfaffl, 2001 ).
Western blot
Protein was extracted from human colonic mucosal strips after incubation in lysis buffer 15PGDH and GAPDH were scanned and subjected to densitometry analysis, and the results were expressed relative to GAPDH.
Immunohistochemistry
Full-thickness pieces of normal human colon (n=6) were fixed in Zamboni's solution.
Paraffin-embedded sections were cut and mounted on poly-L-lysine coated slides.
Reduction of p eroxidases was accomplished by incubating in H 2 O 2 (3%) for 5-10 min at room temperature followed by nonspecific protein blocking (2% horse or goat serum) for 30 min. Sections were incubated with primary antibodies overnight at room temperature.
Primary antibodies used were mouse monoclonal COX-1 antibody (1:500), mouse monoclonal COX-2 antibody (1:100) and rabbit polyclonal 15-PGDH antibody (1:50).
Sections were then washed thoroughly and incubated with biotinylated horse anti-mouse or goat anti-rabbit secondary antibodies (1:2000) for 2 h, followed by avidin-biotinylated enzyme complex for 1 h. Immunoreactivity was visualized by reaction with the substrate diaminobenzidine. Each experiment included a negative control incubated with secondary antibody alone; these consistently exhibited no immunoreactivity.
Immunohistochemistry was also performed in tissue explants (n=7) incubated in the presence or absence of HK-1 (0.1 µM) for 4 h. The experimental procedures were the same as mentioned above.
Statistical analyses
Data for PGE 2 ELISA and Western blot densitometry were normally distributed, and expressed as mean ± SEM. The means were compared using unpaired or paired Student's t test. In addition, one way analysis of variance (ANOVA) was used with a post (NewmanKeuls) test to determine the difference between groups. Real-time PCR data were nonparametric and expressed as median. Thus, Wilcoxon test was used to compare pair-matched medians. All data analyses were performed using GraphPad Prism (Version 5, GraphPad
Software, San Diego, CA, USA). P values of less than 0.05 were considered to indicate a significant difference. 
Results
Time course of HK-1-induced PGE 2 production in mucosa and muscle
To investigate whether HK-1 causes PGE 2 production in colonic muscle and mucosa, paired tissue explants were incubated with or without HK-1 (0.1 μ M) for 0 h to 8 h. HK-1 induced PGE 2 release into bath fluid, in a time-dependent manner ( Figure 1A and B). There was a trend for an increase in PGE 2 release with the time in unstimulated tissues, but this was not significant. After incubation with HK-1 for 1 and 2 h, the PGE 2 levels were no different from unstimulated paired time controls. In the mucosa, PGE 2 levels showed a 10-fold increase (p<0.01) after 4 h and a 2-fold increase (p<0.05) after 8 h, compared with paired time controls ( Figure 1A ). In muscle, there was a 3.5-fold increase in PGE 2 release (p<0.01) after 4 h, whereas there was no significant change after 8 h ( Figure 1B ). Thus, 4 h was considered as the optimal time point and used for all subsequent experiments for mucosa and muscle.
Concentration-response relationship of HK-1-induced PGE 2 production in mucosa and muscle
After 4 hours incubation with HK-1, PGE 2 release from both mucosa and muscle showed a bell-shape curve in response to HK-1 in the 0.1 pM to 10 µM range, with the maximum response at 0.1 µM HK-1 (Figure 2A, B) . In mucosal explants, the effects of HK-1 at 0.01, 0.1 µM and 1 µM ( Figure 2A ) were significantly different from the non-stimulated control, whereas the effect of HK-1 in muscle was statistically different from control only at 0.1 µM ( Figure 2B ). In all subsequent experiments, 0.1 µM was used as the optimal concentration of HK-1.
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Effect of inhibitors on responses to HK-1 and SP in mucosal explants
Firstly, we investigated whether PGE 2 production was dependent upon the activation of tachykinin receptors. HK-1-induced PGE 2 production was inhibited to a similar extent by both the NK 1 receptor antagonist SR140333 (44% of inhibition) and the NK 2 receptor antagonist SR48968 (51% of inhibition) (Figure 3 A) . In parallel, SP (0.1 µM) also stimulated PGE 2 production, and this was inhibited by both SR140333 and SR48968 in a virtually identical manner compared with HK-1 (Figure 3 B) . The NK 1 and NK 2 antagonists alone did not affect the basal level of PGE 2 release at 4 h (n=7, data not shown).
To determine which COX isoform was involved in HK-1-and SP-induced PGE 2 production, mucosal strips were pretreated with the non-selective COX inhibitor indomethacin, the COX-1 selective inhibitor SC-560 or the COX-2 selective inhibitor NS-398. Both HK-1-and SP-induced PGE 2 production was unaffected by SC-560 (Figure 4 ).
However, it was notable that indomethacin (n=8, p<0.05) and NS-398 (n=8, p<0.05) not only blocked, but significantly reduced HK-1-stimulated PGE 2 release below unstimulated baseline levels (Figure 4 ).
To determine the role of neurons in PGE 2 release, mucosal explants were incubated in the presence and absence of TTX (0.1 µM). TTX alone significantly increased PGE 2 release by 217 ± 78% over the basal level (n=8, p<0.05), but TTX did not affect HK-1 induced PGE 2 production (205 ± 138%, n=8).
HK-1-regulated COX and 15-PGDH gene expression in mucosal and muscle explants
Paired explants were incubated in the presence and absence of HK-1 (0.1 μ M) for 4 h, and expression of COX-1, COX-2 and 15-PGDH mRNA in the explants was then determined using real-time RT-PCR. Although HK-1 had no effect on levels of COX-1 mRNA ( Figure 5 A, B), it enhanced the expression of COX-2 mRNA by 2.4-fold and 1.5-fold, in mucosal and No significant upregulation of COX-2 expression induced by HK-1 was seen at earlier incubation time points (data not shown).
Exposure of colonic mucosa to HK-1 (0.1 μ M) significantly reduced 15-PGDH mRNA expression by 1.7-fold compared with non-stimulated control samples ( Figure 5E ). We also attempted to demonstrate the expression of 15-PGDH mRNA in muscle explants, but expression was too low (data not shown).
HK-1-regulated COX and 15-PGDH protein expression in mucosal explants
Western blot was used to determine protein expression of COX-1, COX-2 and 15-PGDH in paired mucosal explants, after incubation with or without HK-1 (0.1 μ M) for 4 h ( Figure   6A ). COX-1 protein expression was unaltered by HK-1, but COX-2 expression was significantly increased with 2.7-fold change ( Figure 6A, B) . Notably, HK-1 caused a 1.6-fold reduction (p<0.05) of 15-PGDH protein expression ( Figure 6A, B) .
Localization of COX-1, COX-2 and 15-PGDH immunoreactivity in unstimulated normal human colon
At the antibody concentrations used here, the immunoreactivity (IR) of COX-1 in epithelial, stromal, intestinal smooth muscle and vascular smooth muscle cells was more pronounced than that of COX-2 and 15-PGDH (Table 1 , Figure 7 , 8). COX-1 IR was widespread in human colonic mucosa, muscle and ganglia, as well as vascular smooth muscle (Figure 7 ). COX-2 IR was generally weaker than COX-1, except in submucosal ganglia where intensity was similar. In the epithelium, COX-2 IR was localized primarily at the cell membrane, whereas COX-1 IR showed a cytoplasmic and nuclear expression (Figure 7, 8 ).
Immunostaining for 15-PGDH was mainly cytoplasmic, of moderate intensity similar to that of COX-2. 15-PGDH staining was highly localized, to regions of the mucosa and to submucosal and myenteric ganglia (Figure 7, 8) . Notably, nuclear staining of 15-PGDH was also observed in epithelial cells ( Figure 7C , 8C) and myenteric ganglia ( Figure 7L ).
Furthermore, weak 15-PGDH staining was seen on goblet cells ( Figure 8C ).
In blood vessels, prominent immunostaining of granulocyte-and monocyte-like cells was observed with COX-1, whereas inmmunostaining with COX-2 and 15-PGDH was moderate.
Platelets showed immunoreactivity for all three enzymes (Figure 8 G, H, I ).
HK-1-induced alteration of COX and 15-PGDH immunoreactivity in human colonic mucosa
The immunoreactive staining for COX-1, COX-2 and 15-PGDH appeared less dense in SP and the NK 1 receptor are upregulated in IBD human intestine and in experimental animal models of IBD (Goode et al., 2000; Liu et al., 2011 ). Studies also demonstrate that PGE 2 plays an important role in the pathogenesis of IBD (Sheibanie et al., 2007) . HK-1 has been implicated in immune/inflammation, but little has been reported about its effects in the human colon. In the current work, we investigated the effect of human HK-1 on PGE 2 production in the normal human colon, and precisely defined its actions on COX and 15-PGDH. To our knowledge, this is the first study simultaneously evaluating the proinflammatory effects of HK-1 and SP in normal human gut. This extends previous observations showing that exogenous SP stimulates PGE 2 production in human colonic epithelial cells (Koon et al., 2006) , and provides an original finding that similar to SP, HK-1 has the ability to induce PGE 2 release in human colon.
The effect of HK-1 to enhance PGE 2 release in both colonic mucosa and muscle was time-and concentration-dependent. Unusually, a bell-shaped concentration curve was observed, with the maximum response at 0.1 µM HK-1, and a similar phenomenon has been seen in studies with SP in human polymorphonuclear leucocytes (Gallicchio et al., 2009 ).
This bell-shape response indicates that at higher concentrations, desensitization may occur;
tachykinins may bind to other tachykinin receptor subtypes, or may activate different mechanisms which have inhibitory effects on PGE 2 production. Although significant PGE 2 production was elicited in both muscle and mucosa, the greater effects in mucosa (10-fold change) suggest a prominent role for HK-1 in that location. In colonic inflammation, immune cells in the lamina propria could be the primary source of HK-1, since endogenous HK-1 is preferentially expressed in lymphocytes and macrophages in mice (Zhang et al., 2000; Zhang and Paige, 2003) and humans (Klassert et al., 2008) . This is in line with an increased expression of TAC4 gene encoding HK-1 in colonic mucosa in ulcerative colitis (Liu et al., 2011 ).
HK-1 shows strong preference for the NK 1 compared with NK 2 or NK 3 receptor (Bellucci et al., 2002) . Our present findings show that HK-1 and SP signal via both NK 1 and NK 2 receptors to induce PGE 2 release in colonic mucosa. It has been previously reported that SP/NK 1 receptors causes PGE 2 release from rat intrapulmonary bronchi (Szarek et al., 1998) and porcine jejunum (Thorbøll et al 1998 (Cutrufo et al., 1999; Di Sebastiano et al., 1999) , and by our previous work showing an upregulation of TACR1 gene in colonic mucosa of IBD patients (Liu et al., 2011) .
In addition to the activation of the NK 1 receptor pathway, we provide new findings that NK 2 receptors also influence the SP and HK-1-evoked PGE 2 production in the human colon.
A relationship between NK 2 receptors and PGE 2 release has been previously shown in alveolar macrophages (Brunelleschi et al., 1992) urinary bladder (Tramontana et al., 2000) , as well as in normal human colon (Burcher et al., 2008) . A relationship between NK 2 receptors and inflammation was shown in human IBD by Renzi et al. (2000) who demonstrated marked increases in the expression of NK 1 receptors in epithelia and in vascular endothelia, whereas NK 2 receptors were increased in inflammatory cells of lamina propria and activated eosinophils around mucosal crypts. The simultaneous involvement of both NK 1 and NK 2 receptors have also been reported in animal models of inflammation (Cutrufo et al., 1999) and hypersecretion (Turvill et al., 2000) . Our study showing the active role of NK 1 and NK 2 receptors in PGE 2 production may help to explain the significance of upregulated NK 1 and NK 2 receptors in the pathophysiology of IBD. Although NK 1 and NK 2
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18 receptors have significant roles in gut pathophysiology, few drugs targeting these individual receptors have entered the clinic for human use. A promising NK 2 receptor antagonist is being tested for irritable bowel syndrome and may have an effect in inflammation (Quartara et al., 2009 ). Our study implies that a combined use of both receptor antagonists may be more therapeutically beneficial.
The steady-state cellular levels of PGE 2 depend on the relative rate of COX-dependent biosynthesis and 15-PGDH-mediated catabolism. In this study, we demonstrated that HK-1-induced PGE 2 release requires the involvement of COX-2 rather than COX-1. Furthermore, HK-1 induces PGE 2 release at the same concentrations and incubation times found to induce COX-2 gene and protein expressions, which were both upregulated to a similar extent.
Strikingly, we have also provided new insights on the effect of HK-1 on expression of 15-PGDH, the key enzyme responsible for PGE 2 inactivation. Coupled with the marked upregulation of COX-2, HK-1 significantly inhibited 15-PGDH expression at both mRNA and protein level. This finding suggests that HK-1 may have dual effects on PGE 2 production, not only by increased PGE 2 synthesis through upregulation of COX-2, but also by decreased 15-PGDH expression and, hence, reduced degradation of PGE 2 . This, we believe, is the most novel finding of our study. This is in line with a previous study showing a marked reduction of 15-PGDH in colonic mucosa from IBD patients (Otani et al., 2006) .
Our immunohistochemical data in colonic mucosa showed COX-2 as well as COX-1 expression primarily in epithelial cells (upper crypts) and immune cells in lamina propria, with some immunoreactivity also localized to submucosal ganglia. They also revealed that 15-PGDH has a similar pattern of immunoreactivity as COX-1 and COX-2, and represent another novel finding that 15-PGDH is also expressed in neuronal regions. In line with our findings that HK-1 increased PGE 2 in muscle explants, we also found expression of COX-1, COX-2 and 15-PGDH in myenteric ganglia, as well as a weaker expression in longitudinal and circular muscle. Our previous studies have shown that indomethacin enhances contractile responses to NKA in human colonic muscle strips from control and diverticular disease patients, suggesting NK 2 receptor-stimulated release of prostanoids which relax smooth muscle (Burcher et al., 2008) . COX-1 and COX-2 have been shown to be present in the neuromuscular compartment of human colon where they modulate cholinergic excitatory control of colonic motility (Fornai et al., 2005) . Further studies using confocal microscopy are necessary to confirm which neuronal and other markers are colocalized with COX and 15-PGDH. Surprisingly, our data showed that TTX enhanced basal PGE 2 release, but had no effect on HK-1 stimulated PGE 2 production. This suggests that there is an inhibitory neuronal component which can reduce PGE 2 release. However, the lack of effect of TTX on HK-1 induced response is suggestive of epithelial and immune cells as the major cellular source of HK-1-COX-2-derived PGE 2 .
In summary, our study has demonstrated a novel role for HK-1 as an important stimulant for PGE 2 release in human colon, and explored the mechanism involved. This is the first demonstration that HK-1, acting via both NK 1 and NK 2 receptors, upregulates COX-2 expression, an effect shared by SP. We further demonstrate that HK-1-induces 15-PGDH downregulation and this represents an additional mechanism by which HK-1 increases PGE 2 production. This study reveals a mechanistic link between HK-1 and PGE 2 in humans, and Most immunoreactivity was cytoplasmic; * indicates that staining also seen on nuclei. 
